• British Pharmacopoeia Volume I & II
  • Monographs: Medicinal and Pharmaceutical Substances

Cyclizine Hydrochloride

European Union chaplet of stars
scroll to previous hit
scroll to next hit
General Notices

(Ph. Eur. monograph 1092)

bp2013_v1_07_medicinal_and_pharmaceutical_substances_05 cyclizinehydrochloride_1_2012_70_cs.png


C18H22N2,HCl    302.8    305-25-3

Action and use

Histamine H1 receptor antagonist; antihistamine.

Preparations

Cyclizine Injection

Cyclizine Tablets

Dipipanone and Cyclizine Tablets

Ph Eur

DEFINITION

1-(Diphenylmethyl)-4-methylpiperazine hydrochloride.

Content

98.5 per cent to 101.0 per cent (dried substance).

CHARACTERS
Appearance

White or almost white, crystalline powder.

Solubility

Slightly soluble in water and in ethanol (96 per cent).

IDENTIFICATION

First identification   B, E.

Second identification   A, C, D, E.

A. Ultraviolet and visible absorption spectrophotometry (2.2.25).

Test solution (a)  Dissolve 20.0 mg in a 5 g/L solution of sulfuric acid R and dilute to 100.0 mL with the same acid solution.

Test solution (b)  Dilute 10.0 mL of test solution (a) to 100.0 mL with a 5 g/L solution of sulfuric acid R.

Spectral range  240-350 nm for test solution (a); 210-240 nm for test solution (b).

Resolution (2.2.25)  Minimum 1.7.

Absorption maxima  At 258 nm and 262 nm for test solution (a); at 225 nm for test solution (b).

Absorbance ratio  A262/A258 = 1.0 to 1.1.

Specific absorbance at the absorption maximum at 225 nm  370 to 410 for test solution (b).

B. Infrared absorption spectrophotometry (2.2.24).

Comparison   cyclizine hydrochloride CRS.

C. Thin-layer chromatography (2.2.27).

Test solution  Dissolve 10 mg of the substance to be examined in methanol R and dilute to 10 mL with the same solvent.

Reference solution  Dissolve 10 mg of cyclizine hydrochloride CRS in methanol R and dilute to 10 mL with the same solvent.

Plate   TLC silica gel GF 254 plate R.

Mobile phase  concentrated ammonia R, methanol R, methylene chloride R (2:13:85 V/V/V).

Application  20 µL.

Development  Over 2/3 of the plate.

Drying  In air for 30 min.

Detection  Expose to iodine vapour for 10 min.

Results  The principal spot in the chromatogram obtained with the test solution is similar in position, colour and size to the principal spot in the chromatogram obtained with the reference solution.

D. Dissolve 0.5 g in 10 mL of ethanol (60 per cent) R, heating if necessary. Cool in iced water. Add 1 mL of dilute sodium hydroxide solution R and 10 mL of water R. Filter, wash the precipitate with water R and dry at 60 °C at a pressure not exceeding 0.7 kPa for 2 h. The melting point (2.2.14) is 105 °C to 108 °C.

E. It gives reaction (a) of chlorides (2.3.1).

TESTS
pH (2.2.3)

4.5 to 5.5.

Dissolve 0.5 g in a mixture of 40 volumes of ethanol (96 per cent) R and 60 volumes of carbon dioxide-free water R and dilute to 25 mL with the same mixture of solvents.

Related substances

Gas chromatography (2.2.28). Prepare the solutions immediately before use.

Test solution  Dissolve 0.250 g of the substance to be examined in 4.0 mL of methanol R and dilute to 5.0 mL with 1 M sodium hydroxide.

Reference solution (a)  Dissolve 25 mg of the substance to be examined in 10.0 mL of methanol R. Dilute 1.0 mL of this solution to 50.0 mL with methanol R.

Reference solution (b)  Dissolve 5 mg of the substance to be examined, 5.0 mg of cyclizine impurity A CRS and 5.0 mg of cyclizine impurity B CRS in methanol R and dilute to 20.0 mL with the same solvent.

Column:
  • material: fused silica;
  • size: l = 25 m, Ø = 0.33 mm;

Carrier gas  helium for chromatography R.

Flow rate  1.0 mL/min.

Split ratio  1:25.

Temperature:

bp2013_v1_07_medicinal_and_pharmaceutical_substances_05 cyclizinehydrochloride_2_2012_70_tb.png


Detection  Flame ionisation.

Injection  1 µL.

Relative retention  With reference to cyclizine (retention time = about 15 min): impurity A = about 0.2; impurity B = about 0.7.

System suitability  Reference solution (b):

  • peak-to-valley ratio: minimum 50, where Hp = height above the baseline of the peak due to impurity A and Hv = height above the baseline of the lowest point of the curve separating this peak from the peak due to methanol.
Limits:
  • impurities A, B: for each impurity, not more than the area of the corresponding peak in the chromatogram obtained with reference solution (b) (0.5 per cent);
  • unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);
  • total: not more than 10 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent);
  • disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).
Loss on drying (2.2.32)

Maximum 1.0 per cent, determined on 1.000 g by drying in an oven at 130 °C.

Sulfated ash (2.4.14)

Maximum 0.1 per cent, determined on 1.0 g.

ASSAY

In order to avoid overheating in the reaction medium, mix thoroughly throughout and stop the titration immediately after the end-point has been reached.

Dissolve 0.120 g in 15 mL of anhydrous formic acid R and add 40 mL of acetic anhydride R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20).

1 mL of 0.1 M perchloric acid is equivalent to 15.14 mg of C18H23ClN2.

STORAGE

Protected from light.

IMPURITIES

Specified impurities   A, B.

bp2013_v1_07_medicinal_and_pharmaceutical_substances_05 cyclizinehydrochloride_3_2012_70_cs.png


A. 1-methylpiperazine,

bp2013_v1_07_medicinal_and_pharmaceutical_substances_05 cyclizinehydrochloride_4_2012_70_cs.png


B. diphenylmethanol (benzhydrol).

Ph Eur